Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839235 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
A Phase 1 study of Primary Hyperoxaluria Type 1 (PH1), sponsored by Arbor Biotechnologies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT06839235 is a Phase 1 study of Primary Hyperoxaluria Type 1 (PH1) that is actively recruiting participants, run by Arbor Biotechnologies. The registered enrollment target is 23 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT06839235, a Phase 1 study of Primary Hyperoxaluria Type 1 (PH1), is actively recruiting participants, sponsored by Arbor Biotechnologies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.
Conditions Studied
Interventions
- DRUG ABO-101
Study Locations (7)
Other
- Hospices Civils de Lyon- Hôpital Femmes Mères Enfants - Lyon
- Kindernierenzentrum Bonn - Bonn
- Heidi Chaker - Sfax
- Queen Elizabeth Hospital Birmingham - Birmingham
- Royal Free Hospital - London
Minnesota
- Mayo Clinic - Rochester
- Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2043-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06839235
The ClinicalTrials.gov registry entry for NCT06839235 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Biotechnologies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Hyperoxaluria Type 1 (PH1) appearing as the primary indexed condition, and to 1 intervention - of which ABO-101 is the first listed.
NCT06839235 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06839235 about?
NCT06839235 is a clinical study titled "Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)". The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult partic...
What is the current status of trial NCT06839235?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2025-06-16. Estimated completion is 2043-02.
What conditions does trial NCT06839235 study?
This clinical trial studies the following conditions: Primary Hyperoxaluria Type 1 (PH1).
What interventions are being tested in trial NCT06839235?
The interventions under investigation include: ABO-101 (DRUG).
Who is sponsoring clinical trial NCT06839235?
This trial is sponsored by Arbor Biotechnologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839235 being conducted?
This trial has 7 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperoxaluria Type 1 (PH1)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.